NEW YORK – Caris Life Sciences and Cota announced on Tuesday a partnership to support biopharmaceutical drug development and patient care through expanded multi-modal data offerings.

纽约–Caris Life Sciences和Cota于周二宣布建立合作伙伴关系，通过扩展多模式数据提供来支持生物制药药物开发和患者护理。

Under the terms of the agreement, the financial details of which were not provided, Caris will combine its genomic, transcriptomic, proteomic and imaging data with Cota's electronic health record data from over 2 million treated cancer patients 'to power the next wave of cancer therapeutics,' the firms said in a statement..

该公司在一份声明中表示，根据协议条款（未提供财务细节），Caris将其基因组学、转录组学、蛋白质组学和成像数据与Cota 200多万癌症患者的电子健康记录数据相结合，为下一波癌症治疗提供动力。。

'Caris' partnership with Cota will enable biopharma to leverage a more complete dataset to power research and AI approaches for therapeutic development,' Brian Lamon, chief business officer at Caris, said in a statement. 'This breadth of data allows the flexibility to build specific cohorts for understanding mechanisms of resistance, determinants of response and relevant biomarkers to improve success of their clinical trials.' .

Caris首席商务官布莱恩·拉蒙（BrianLamon）在一份声明中说，Caris与Cota的合作将使生物制药能够利用更完整的数据集来推动研究和人工智能方法的治疗发展这种广泛的数据允许灵活地建立特定的队列，以了解耐药机制，反应的决定因素和相关的生物标志物，以提高其临床试验的成功率。”。

Caris has been actively pursuing several drug discovery and development partnerships across the oncology space. Earlier this month, the Irving, Texas-based company partnered with Germany's Merck KGaA to accelerate the development of first-in-class antibody-drug conjugates for cancer patients through Caris Discovery, its therapeutic research arm.

Caris一直在肿瘤领域积极寻求几种药物发现和开发合作伙伴关系。本月早些时候，这家总部位于德克萨斯州欧文的公司与德国默克公司（Merck KGaA）合作，通过其治疗研究部门Caris Discovery，加速为癌症患者开发一流的抗体-药物偶联物。

The month prior, Caris announced a deal with the Beat Childhood Cancer Research Consortium to advance pediatric precision oncology research..

前一个月，Caris宣布与Beat Children Cancer Research Consortium达成协议，以推进儿科精准肿瘤学研究。。

'By combining Cota's high-quality, curated data sourced from electronic health records with Caris' molecular data, life sciences researchers will be able to capture previously unseen insights to optimize cancer treatments that can improve a patient's prognosis and quality of life,' said C.K. Wang, chief medical officer of Cota..

Cota首席医疗官C.K.Wang说：“通过将Cota从电子健康记录中获得的高质量精选数据与Caris的分子数据相结合，生命科学研究人员将能够捕捉到以前看不到的见解，以优化癌症治疗，从而改善患者的预后和生活质量。”。。